Cardioprotective potential of oleuropein, hydroxytyrosol, oleocanthal and their combination: Unravelling complementary effects on acute myocardial infarction and metabolic syndrome
Redox Biology,
Год журнала:
2024,
Номер
76, С. 103311 - 103311
Опубликована: Авг. 14, 2024
Clinical
studies
have
previously
established
the
role
of
olive
products
in
cardiovascular
disease
(CVD)
prevention,
whilst
identification
responsible
constituents
for
beneficial
effects
is
still
pending.
We
sought
to
assess
and
compare
cardioprotective
potential
oleuropein
(OL),
hydroxytyrosol
(HT),
oleocanthal
(OC)
oleanolic
Acid
(OA),
regarding
Ischemia/Reperfusion
Injury
(IRI)
CVD
risk
factors
alleviation.
The
scope
study
was
design
a
potent
safe
combinatorial
therapy
high-cardiovascular-risk
patients
on
bench-to-bedside
approach.
evaluated
IRI-limiting
6-weeks
treatment
with
OL,
HT,
OC
or
OA
at
nutritional
doses,
healthy
metabolic
syndrome
(MS)-burdened
mice.
Three
regimens
were
designed
mixture
preponderant
benefits
(OL-HT-OC,
Combo
2),
including
infarct
sparing
antiglycemic
potency,
compared
isolated
compounds,
further
investigated
its
anti-atherosclerotic
effects.
In
vivo
experiments
revealed
that
combination
regimen
2
presented
most
favorable
limiting
size
hyperglycemia,
which
selected
be
clinical
setting
Chronic
Coronary
Artery
Syndrome
(CCAS)
patients.
Cardiac
function,
inflammation
markers
oxidative
stress
assessed
baseline
after
4
weeks
OL-HT-OC
supplement
study.
found
significantly
reduced
Controls.
OL
exhibited
antihyperglycemic
properties
attenuated
hypercholesterolemia.
OL-HT-OA,
OL-HT-OC-OA
cardioprotective,
whereas
only
mitigated
hyperglycemia.
cardioprotection
attributed
apoptosis
suppression,
enhanced
antioxidant
upregulation
enzymes.
Additionally,
it
atherosclerotic
plaque
extent
vivo.
ameliorated
cardiac,
vascular
endothelial
function
small-scale
Conclusively,
exerts
vivo,
remarkable
clinically
translatable
high-risk
Язык: Английский
Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
Frontiers in Pharmacology,
Год журнала:
2025,
Номер
16
Опубликована: Март 27, 2025
The
survival
rates
of
patients
with
hematological
malignancies
such
as
multiple
myeloma
have
improved
advances
in
cancer
treatment.
However,
the
risk
cardiovascular
disease
associated
novel
therapeutic
agents,
including
proteasome
inhibitors
(PIs),
is
becoming
increasingly
evident.
PIs
act
on
peptidases,
leading
to
cell
cycle
arrest
or
apoptosis.
Carfilzomib
(CFZ),
an
intravenously
administered
irreversible
PI,
exhibits
pronounced
toxicity
that
characterized
by
heart
failure,
hypertension,
arrhythmia,
and
ischemic
(IHD).
This
review
focuses
CFZ,
details
its
applications
treating
myeloma,
presents
potential
mechanisms
cardiotoxicity
incidence
cardiotoxic
events,
provides
recommendations
for
evaluation
management
adverse
cardiac
events
during
early
treatment
this
drug.
Язык: Английский
Antifungal effects of Metformin against Candida albicans by autophagy regulation
The Journal of Microbiology,
Год журнала:
2025,
Номер
63(4), С. e2411008 - e2411008
Опубликована: Апрель 29, 2025
Язык: Английский
Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(14), С. 7795 - 7795
Опубликована: Июль 16, 2024
This
study
investigates
the
association
between
circulating
microRNA
(miRNA)
expression
and
cardiovascular
adverse
events
(CVAE)
in
multiple
myeloma
(MM)
patients
treated
with
a
carfilzomib
(CFZ)-based
regimen.
A
cohort
of
60
MM
from
Prospective
Observation
Cardiac
Safety
Proteasome
Inhibitor
(PROTECT)
was
analyzed.
Among
these,
31
(51.6%)
developed
CVAE
post-CFZ
treatment.
The
Taqman
OpenArray
Human
panels
were
used
for
miRNA
profiling.
We
identified
13
differentially
expressed
miRNAs
at
baseline,
higher
expressions
miR-125a-5p,
miR-15a-5p,
miR-18a-3p,
miR-152-3p
lower
miR-140-3p
who
later
compared
to
those
free
CVAE,
adjusting
age,
gender,
race,
B-type
natriuretic
peptide
levels.
also
three
miRNAs,
including
miR-150-5p,
that
without
post-treatment.
Additionally,
five
responded
differently
CFZ
treatment
vs.
non-CVAE
patients,
significantly
elevated
post-treatment
miR-598,
miR-152,
miR-21,
miR-323a
patients.
Pathway
enrichment
analysis
highlighted
involvement
these
diseases
vascular
processes.
These
findings
suggest
specific
could
serve
as
predictive
biomarkers
provide
insights
into
underlying
mechanisms
CFZ-CVAE.
Further
investigation
is
warranted
before
can
be
applied
clinical
settings.
Язык: Английский